

From courses to careers: A Pharmaceutical perspective

Brad Evans, Ph.D.

Pfizer Global Research and Development

Specific Opportunities

- **Preclinical – Discovery**
- **PDM**
- **Toxicology**
- **Pharmaceutical Sciences**
- **Drug manufacturing**
 - A series of funnels or filters**
- **Apply Statistical methods to help drive decisions**

Early Discovery

- Find something that does something..
- Target: scientific literature, market research
- High Throughput Screening / Discovery Biology
 - DOE for Assay Design
 - Control Charting
 - Exploratory Data Analysis
 - Non-linear Dose Response Models
 - Multiple Comparisons
 - Structure Activity Relationship (PLS, SVM, etc)
- How do we modify a molecule that is “close”?
- How do we select which compounds will continue?

Early Discovery

- Dose Response / Non Linear Model
 - Variance – constant, proportional?
 - Transform: $x?$, $y?$ both?
- Data fitting or coefficients with intrinsic meaning?
 - Rate of binding
 - Coefficients may tell the scientists what mechanism(s) are at work
- 2x2 table but 99%+ in one cell?

PDM (Pharmacokinetics, Dynamics and Metabolism)

- ▣ What the drug does to the body
- ▣ What the body does to the drug
- ▣ More in-depth information on fewer compounds..
- ▣ Dose response:
 - ▣ T_{max} , C_{max} , AUC, half-life
 - ▣ Non-linear modeling
- ▣ Battery of safety assays
- ▣ How do we “build” and assess the assays?
- ▣ How do we select which compounds continue?
- ▣ Is the “best” good enough?
- ▣ Do in-vitro (lab) and in-vivo (animal) data:
 - ▣ Correlate?
 - ▣ Substitute?

Safety / Toxicology

- How does the drug perform in animal studies?
 - Is there a dose response?
 - Is there a safety window?
 - Are any systems negatively impacted?
 - Kidney, liver, brain, body weight, heart function?
 - Are the offspring impacted? (Thalidomide)
 - Limited “n” (want to “prove” no Adverse Events)
- One study may “kill” a compound
- ANOVA, Dose trending, multiple comparisons
- Reporting, validation and documentation much more stringent compared to early discovery

Pharmaceutical Development

- If a compound works, how can we make it?
 - Chemical synthesis (DOE, EDA)
 - Biological process – grow cells, clean cells (DOE)
- How can we test it? (Analytical methods)
 - Method development
 - Method precision, linearity, bias, robustness
 - Do we have uniformity in our tablets and capsules?
 - Does our delayed release formulation work as intended?
- How can we preserve its functionality over time?
 - Formulation (DOE, Mixture Experiments)
 - Stability Testing (Regression, ANCOVA)
- Overall, do all three pieces above have a robust, controlled process? (Quality by Design)
 - Lab → Pilot → Commercial scale (DOE, modeling)
 - Testing to support label claims, product performance over time

Global Supply (Manufacturing)

- Process Control, process capability
- Investigational work , annual reviews
- What process variables are contributing to process variation?
- Changes: facility, supplier, method, reagent
- Can we improve our process: time, \$\$, greener?
 - DOE
 - Total Quality Management / Six Sigma